620 results on '"Qin, Lun-Xiu"'
Search Results
2. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives
3. Acetyl-CoA metabolic accumulation promotes hepatocellular carcinoma metastasis via enhancing CXCL1-dependent infiltration of tumor-associated neutrophils
4. Ex vivo liver resection and auto-transplantation as an alternative for the treatment of liver malignancies: Progress and challenges
5. Single-cell mapping reveals several immune subsets associated with liver metastasis of pancreatic ductal adenocarcinoma
6. Modulation of cellular metabolism by protein crotonylation regulates pancreatic cancer progression
7. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma
8. Biomarkers for response to immunotherapy in hepatobiliary malignancies
9. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma
10. Alpha5 nicotine acetylcholine receptor subunit promotes intrahepatic cholangiocarcinoma metastasis
11. MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming
12. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives
13. Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and ΔNp63
14. GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages
15. Author Correction: Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and ΔNp63
16. ACOT12-Dependent Alteration of Acetyl-CoA Drives Hepatocellular Carcinoma Metastasis by Epigenetic Induction of Epithelial-Mesenchymal Transition
17. Expert consensus—promoting clinical excellence and ultimately benefitting patients
18. FOXQ1/NDRG1 axis exacerbates hepatocellular carcinoma initiation via enhancing crosstalk between fibroblasts and tumor cells
19. Current perspectives of cancer-associated fibroblast in therapeutic resistance: potential mechanism and future strategy
20. Development and validation of a mutation-annotated prognostic score (MAPS) for intrahepatic cholangiocarcinoma after resection: a retrospective cohort study
21. Adjuvant Lenvatinib in Combination with Transarterial Chemoembolization for Hepatocellular Carcinoma Patients with High-Risk of Postoperative Recurrence: A Prospective Cohort Study
22. Isolation and characterization of exosomes for cancer research
23. Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response
24. Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma.
25. Adjuvant Lenvatinib in Combination with Transarterial Chemoembolization for Hepatocellular Carcinoma Patients with High-Risk of Postoperative Recurrence (LANCE): A Multicenter Prospective Cohort Study
26. Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma
27. Core fucosylated glycan-dependent inhibitory effect of QSOX1-S on invasion and metastasis of hepatocellular carcinoma
28. Supplementary Data from Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAM+ Hepatocellular Carcinoma
29. Data from Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAM+ Hepatocellular Carcinoma
30. Supplementary Data from Human Hepatocellular Carcinoma Tumor–derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells
31. CCR Translation for the Article from Human Hepatocellular Carcinoma Tumor–derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells
32. Supplementary Data from Gene Expression Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma
33. Supplementary Data from Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma
34. Supplementary Methods, Figures 1 - 7, Tables 1 - 10 from Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma
35. Data from Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma
36. Supplementary Tables 1-4, Figure Legend from Association of Specific Genotypes in Metastatic Suppressor HTPAP with Tumor Metastasis and Clinical Prognosis in Hepatocellular Carcinoma
37. Data from A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma Patients
38. Data from EpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
39. Supplementary Figures 1-3, Table 1 from A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma Patients
40. Supplementary Text, Figures 1-3, Tables 1-6 from EpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
41. Supplementary Figure 1 from Association of Specific Genotypes in Metastatic Suppressor HTPAP with Tumor Metastasis and Clinical Prognosis in Hepatocellular Carcinoma
42. Data from Association of Specific Genotypes in Metastatic Suppressor HTPAP with Tumor Metastasis and Clinical Prognosis in Hepatocellular Carcinoma
43. The application of real-time indocyanine green fluorescence cholangiography in laparoscopic living donor left lateral sectionectomy
44. Development and Validation of a Mutation-Annotated Prognostic Score (MAPS) for Intrahepatic Cholangiocarcinoma
45. Molecular Events on Metastasis of Hepatocellular Carcinoma
46. Immunotherapy for hepatobiliary malignancies: Progress and prospective
47. Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin
48. Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma
49. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities
50. Prospero‐related homeobox 1 drives angiogenesis of hepatocellular carcinoma through selectively activating interleukin‐8 expression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.